17607 Gold Plaza, Omaha, NE
402-991-8468
Patient Portal
Menu

Welcome to the Urology Cancer Center

We are the region’s only cancer center dedicated solely to the treatment and research of prostate, kidney, bladder and testicular cancers. Our team of over 30 dedicated professionals have one mission: to provide each patient unsurpassed personalized cancer care accomplished through deep heartfelt compassion, extensive and comprehensible education, the most proficient cancer management, and an unparalleled focus on improving survival and quality of life.

Urology Cancer Center

We utilize a unique team approach: Dr. Luke and his Clinical Team, Research Coordinators, Treatment Nurses, Pharmacy, Scheduling and Financial staff work simultaneously during a patient’s visit to ensure delivery of the most accurate, personalized, efficient and expert care.

Learn More

Cancer Research

Dr. Luke's research team has access to potentially life-prolonging treatments years before they are available to the public. With our access to a growing pipeline of new drugs on clinical trials, UCC has the most available treatment options for urologic cancers compared to all other major centers.

Learn More

Patient Resources & Financial Assistance

We understand the financial burdens cancer may cause a patient and their family. We have highly trained and compassionate staff when it comes helping you choose the most appropriate insurance plans and obtaining assistance to minimize your out- of-pocket costs.

Learn More

Patient Testimonials

I cannot begin to tell you what I was feeling after I found out that my cancer had reared its ugly head again.. Fortunately a close friend of mine suggested that I talk to Dr. Luke.. OMG!! After seeing so many doctors, hospitals etc. you tend to get frustrated to say the least but the moment I stepped into the office of Dr. Luke...at ease.. It was amazing. It was total ZEN. I really don't think that I have ever been so relaxed in a doctor's office. EVERYONE was so nice and kind. When I met Dr. Luke it was instant...I think this guy is going to help me. He gets it!! He knows it!! and he is going to HELP me make the right decisions toward my future health issues. He is up on and pilots all the new break-through studies and trials that are current and what is in the pipeline. I truly believe that we are going to have a very long relationship. With his guidance I know that I may have the cancer but HE is going to help me LIVE with it.. He, in my opinion, is SUPERB and I thank you Dr. Luke for your encouragement.

Prostate Cancer Patient
Read All Testimonials

Meet Our Team

Experts working together for your best outcome.

Luke Nordquist, M.D., F.A.C.P.

CEO, Urologic Medical Oncologist

Learn More

Jill Danahay MSN, APRN

Nurse Practitioner

Learn More

Kelly Hastings MSN APRN

Nurse Practitioner

Learn More

Click each logo to learn about our certifications.

QOPI Certification Program NCQA Certification

A Global Leader in Prostate Cancer Research

Cancer research is the only process available to discover and utilize new treatments for cancer patients. The Urology Center & GU Research Network is recognized by thought leaders, patients and pharmaceutical companies as a global leader in research.

Learn More

Upcoming Events

Christmas Office Hours (Closed 12/22/17 and 12/25/17)

Learn More

Recent News

The Real-Life Patient Impact of Pharmacy Benefit Managers

January 10, 2018

There is growing awareness of the problems and pitfalls with Pharmacy Benefit Managers (PBMs)
in the United States health care system. Contracted by insurance carriers to negotiate on their
behalf with pharmaceutical companies, these ‘middle men’ corporations have quietly become an
unavoidable part of our nation’s health care system.

Download Article

Apalutamide Granted FDA’s Priority Review for Nonmetastatic CRPC

December 26, 2017

Based on data from the phase III SPARTAN trial (ARN-509-003), apalutamide (ARN-509) has been granted a priority review by the FDA for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.

View Article
All News